Related Experiment Video
Updated: Aug 4, 2026

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
Published on: January 29, 2017
Psychotropic analgesic nitrous oxide for treating alcohol withdrawal in an outpatient setting
1South African Brain Research Institute, Waverely, Johannesburg.
Abstract:
In a retrospective study of 500 patients we present evidence that psychotropic analgesic nitrous oxide (PAN) can be used safely and successfully as an out-patient treatment for the AWS in the vast majority of cases. A feature of the PAN therapy is the rapidity of recovery of patients within 60 minutes; which is in stark contrast to that found when traditional benzodiazepine medication regimens are used. Our work confirms earlier findings confined to in-patients. Importantly, the requirements for addictive sedative medications is also dramatically reduced, greatly diminishing the dangers of secondary addiction. In a small number of cases PAN can be used to treat alcohol craving, which may prevent relapses through its positive effects on reducing craving. The promising, rapid anti-craving effects of PAN would seem to require further investigation to establish when it is likely to be of benefit in preventing relapse. In order to maximize the benefit of the PAN treatment to both patient and physician it is essential for the physician to undergo a short hands-on training course.
More Related Videos
14:52Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
Published on: January 13, 2018
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Related Concept Videos
CNS Depressants: Alcohol and Nicotine
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Parenteral Anesthetics: Overview
Inhalational Anesthetics: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drug Delivery: Enteral Route
Drugs in...